Ranbaxy scrip plummets 17 percent as investors panic
Facebook Twitter google+ RSS Feed

Ranbaxy scrip plummets 17 percent as investors panic

Thursday, 26 February 2009, 10:07 Hrs
Printer Print Email Email
Mumbai: Ranbaxy Laboratories' stock fell a drastic 17 percent Thursday as investors panicked after the U.S. Food and Drug Administration (FDA) halted review of drug applications from the Indian drug major, alleging falsification of data and test results.

The Ranbaxy scrip, which ended Wednesday's trade on the Bombay Stock Exchange (BSE) at 207.25, was trading at 173.30, down 16.38 percent, around 1 p.m. Thursday.

Announcing the action, the FDA said Wednesday that it was continuing to investigate the matter to ensure safety and efficacy of marketed drugs associated with Ranbaxy's Paonta Sahib site in Himachal Pradesh.

Over 4.2 million shares changed hands as investors got jittery over the action and the drug company's image took a beating.

Last September, the FDA had issued two warning letters and instituted an import alert barring the entry of all finished drug products and active pharmaceutical ingredients from Ranbaxy's Dewas (Madhya Pradesh), Batamandi (Himachal Pradesh) and Paonta Sahib facilities due to violations of current US Good Manufacturing Practices requirements.

That action barred the commercial importation of 30 different generic drugs into the US and remains in effect.

In a press statement, Ranbaxy Laboratories said it will analyse the letter from the FDA informing it about action against the Paonta Sahib facility, placing it under a policy entitled Application Integrity Policy (AIP), and "respond appropriately in a timely manner".
Source: IANS
Experts on SiliconIndia
Santhosh  K
Sr. Soft. Engg.
Oracle India
Nehal Vyas
Sr. Team Lead
Cyberoam Tech.
Rani Malli
Sr. Director
Sr. Executive
Vijay Balkrishna Konduskar
Business Consultant
Imans Web Tech
Dr L P  Sharma
Technical Director
Reena Khanna
Dellas  Asse
sys-network admin
Computer Station
Write your comment now
Submit Reset